In our quest to gain a comprehensive understanding of the implications of aberrant EFTUD2 expression in CRC, we embarked on an extensive analysis delving into the relationship between EFTUD2 expression and clinical-pathological parameters, leveraging data from patients within the TCGA cohort. This evidence concerns the gene EFTUD2 and colorectal carcinoma.